Drugs for Gastrointestinal Diseases Practice Questions

Q: Erythromycin is given in intestinal hypomotility because:

It binds to motilin receptors. **Explanation:** **Mechanism of Action (Why D is correct):** Erythromycin, a macrolide antibiotic, acts as a **prokinetic agent** by mimicking the action of the endogenous peptide hormone **motilin**. It acts as a non-peptide motilin receptor agonist. These receptors are primarily located on the smooth muscles of the gastrointestinal tract (stomach and duodenum). Binding to these receptors triggers **Migrating Motor Complexes (MMCs)**, which stimulate gastric emptying and intestinal motility. **Analysis of Incorrect Options:** * **Options A & B:** While Erythromycin is an antibiotic that affects bacterial counts, its prokinetic effect is independent of its antimicrobial properties. In the context of intestinal hypomotility, the therapeutic benefit is mechanical (motility) rather than microbiological. * **Option C:** Erythromycin does not have a direct clinical mechanism involving the binding of adenylyl cyclase to treat hypomotility. Prokinetic action is mediated through calcium signaling and motilin pathways, not primarily through the cAMP/adenylyl cyclase system. **Clinical Pearls for NEET-PG:** * **Indications:** It is the drug of choice for **Diabetic Gastroparesis** and is also used in intestinal pseudo-obstruction (Ogilvie’s syndrome). * **Dose:** The prokinetic effect occurs at **lower doses** (e.g., 40–250 mg) than those required for antimicrobial activity. * **Tachyphylaxis:** A major limitation of using Erythromycin as a prokinetic is the rapid development of tolerance (tachyphylaxis) due to down-regulation of motilin receptors. * **Side Effects:** The most common side effect is abdominal cramping/diarrhea, which is essentially an extension of its prokinetic pharmacological action.

Q: Ursodiol reduces the size of common bile duct gallstones by which mechanism?

Slowly dissolving cholesterol from the stone. **Explanation:** **Mechanism of Action (Why D is correct):** Ursodiol (Ursodeoxycholic acid) is a naturally occurring bile acid. It reduces the size of gallstones primarily by **decreasing the cholesterol saturation index** of bile. It achieves this by: 1. Inhibiting the intestinal absorption of cholesterol. 2. Suppressing hepatic cholesterol synthesis and secretion into the bile. By creating a "cholesterol-unsaturated" environment, Ursodiol promotes the **gradual solubilization (dissolution)** of cholesterol from the surface of the stone into the bile. **Analysis of Incorrect Options:** * **Option A:** Ursodiol does not decrease the overall synthesis of bile; rather, it changes the *composition* of bile, making it richer in hydrophilic bile acids. * **Option B:** Increasing cholesterol content would promote stone formation (lithogenic bile). Ursodiol does the opposite—it **decreases** cholesterol content. * **Option C:** Ursodiol has no effect on calcium. It is ineffective against calcified (radiopaque) stones or pigment stones; it only works on radiolucent **cholesterol stones**. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Small, radiolucent cholesterol gallstones in patients who are poor surgical candidates; Primary Biliary Cholangitis (PBC). * **Prerequisite for use:** The gallbladder must be functional (patent cystic duct) to allow the drug-enriched bile to reach the stones. * **Limitation:** Treatment is slow (months to years) and recurrence is common once the drug is stopped. * **Drug Interaction:** Bile acid sequestrants (Cholestyramine) and Aluminum-containing antacids can bind Ursodiol and decrease its absorption.

Q: Which drug is most effective in inhibiting gastric acid output throughout the day?

Omeprazole. **Explanation:** **1. Why Omeprazole is the Correct Answer:** Omeprazole is a **Proton Pump Inhibitor (PPI)**. It works by irreversibly inhibiting the **H+/K+ ATPase enzyme** (the "proton pump"), which is the final common pathway for gastric acid secretion in parietal cells. Unlike other drugs that block specific receptors (like H2 or M3), PPIs shut down the pump itself. Because the inhibition is irreversible, acid secretion only resumes after new enzyme molecules are synthesized (taking 24–48 hours). This results in the most potent and prolonged suppression of both basal and stimulated gastric acid output throughout the day and night. **2. Why the Other Options are Incorrect:** * **B. Cimetidine:** This is an **H2-receptor antagonist**. While effective, it only blocks the histamine-mediated pathway. Gastrin and Acetylcholine can still stimulate the proton pump, making it less efficacious than PPIs. * **C. Pirenzepine:** This is a selective **M1-muscarinic antagonist**. It reduces vagally stimulated acid secretion but is significantly less potent than H2 blockers or PPIs and is rarely used clinically for this purpose today. * **D. Misoprostol:** This is a **PGE1 analogue**. While it inhibits acid and provides cytoprotection, its primary role is preventing NSAID-induced ulcers. Its acid-inhibitory potency and duration are inferior to Omeprazole. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** PPIs are the DOC for GERD, Peptic Ulcer Disease, and Zollinger-Ellison Syndrome. * **Pharmacokinetics:** PPIs are **prodrugs**, administered as enteric-coated formulations to prevent degradation by stomach acid. They are activated in the acidic environment of the **canaliculi** of parietal cells. * **Timing:** For maximum efficacy, PPIs should be taken **30–60 minutes before a meal** (usually breakfast) to coincide with the maximum activation of proton pumps.

Q: Aprepitant is used as:

Antiemetic. **Explanation:** **Aprepitant** is a selective, high-affinity antagonist at the **Substance P/Neurokinin-1 (NK1) receptors** located in the brainstem (area postrema and nucleus tractus solitarius). By blocking these receptors, it inhibits the emetic reflex triggered by Substance P. It is primarily used as an **antiemetic**, specifically for the prevention of both acute and delayed phases of **Chemotherapy-Induced Nausea and Vomiting (CINV)**, often in combination with 5-HT3 antagonists (like Ondansetron) and Dexamethasone. **Analysis of Incorrect Options:** * **A. Antidepressant:** While Substance P is involved in mood regulation, NK1 antagonists have not shown significant efficacy in treating clinical depression. Standard antidepressants include SSRIs, SNRIs, or TCAs. * **C. Antihypertensive:** Aprepitant has no effect on peripheral vascular resistance or cardiac output and is not used to lower blood pressure. * **D. Diuretic:** It does not influence renal electrolyte handling or water excretion. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** NK1 receptor antagonist (blocks Substance P). * **Fosaprepitant:** This is the water-soluble **prodrug** of Aprepitant, administered intravenously. * **Drug Interactions:** Aprepitant is a substrate, moderate inhibitor, and inducer of **CYP3A4**. It can increase levels of drugs like Dexamethasone (dose reduction required) and decrease the efficacy of Warfarin and oral contraceptives. * **Clinical Use:** It is the drug of choice for **delayed emesis** associated with highly emetogenic chemotherapy (e.g., Cisplatin).

Q: All of the following statements are true regarding ondansetron except?

It has significant drug interactions.. ### Explanation **Ondansetron** is a prototype 5-HT3 receptor antagonist widely used in clinical practice. **Why Option C is the correct answer (The False Statement):** Ondansetron is known for its **excellent safety profile** and **minimal drug-drug interactions**. It is metabolized by the hepatic cytochrome P450 system (CYP3A4, CYP2D6, and CYP1A2), but it does not significantly inhibit or induce these enzymes. Unlike many other drugs used in oncology or GI medicine, it rarely requires dose adjustments when co-administered with other medications, making it a preferred choice in multi-drug regimens. **Analysis of Incorrect Options:** * **Option A:** It remains the **first-line drug (DOC)** for preventing and treating chemotherapy-induced nausea and vomiting (CINV), as well as radiotherapy-induced and postoperative vomiting. * **Option B:** Its primary mechanism is the **competitive blockade of 5-HT3 receptors** located both peripherally (on vagal afferents in the GI tract) and centrally (in the Chemoreceptor Trigger Zone/CTZ). * **Option D:** While primarily a 5-HT3 antagonist, some studies suggest ondansetron may possess weak **5-HT4 agonism**, which might contribute to its effects on GI motility, though this is not its main clinical mechanism. **High-Yield NEET-PG Pearls:** * **Side Effects:** The most common side effects are **headache** and **constipation**. * **ECG Changes:** A critical high-yield fact is that ondansetron can cause **QT interval prolongation**; caution is required in patients with electrolyte imbalances or congenital long QT syndrome. * **Site of Action:** It acts at both the **CTZ** (Central) and the **STN/Vagal nerve endings** (Peripheral). * **Ineffectiveness:** It is **not effective** in Motion Sickness (where H1 and M1 blockers are used).

Q: What is the drug of choice for cisplatin-induced emesis?

Ondansetron. **Explanation:** **Correct Answer: C. Ondansetron** Cisplatin is a highly emetogenic chemotherapy agent. It causes nausea and vomiting by damaging enterochromaffin cells in the gastrointestinal tract, leading to a massive release of **serotonin (5-HT)**. This serotonin stimulates **5-HT₃ receptors** on vagal afferents and in the Chemoreceptor Trigger Zone (CTZ). **Ondansetron**, a selective 5-HT₃ receptor antagonist, effectively blocks these receptors, making it the first-line drug of choice for preventing acute chemotherapy-induced nausea and vomiting (CINV). **Analysis of Incorrect Options:** * **A. Metoclopramide:** A D₂ receptor antagonist with prokinetic properties. While used for mild emesis or gastroparesis, it is less effective than 5-HT₃ antagonists for highly emetogenic drugs like cisplatin and carries a risk of extrapyramidal side effects. * **B. Domperidone:** A peripheral D₂ antagonist. It is primarily used for drug-induced nausea (e.g., Levodopa) or GERD but is ineffective against the potent serotonin surge caused by cisplatin. * **C. Octreotide:** A somatostatin analogue used for secretory diarrhea (carcinoid syndrome) or variceal bleeding; it has no role in managing CINV. **NEET-PG High-Yield Pearls:** * **Combination Therapy:** For highly emetogenic chemotherapy (HEC), the current gold standard is a "Triple Regimen": **5-HT₃ Antagonist + Dexamethasone + NK₁ Receptor Antagonist** (e.g., Aprepitant). * **Side Effects:** The most common side effects of Ondansetron are **headache**, constipation, and **QT interval prolongation**. * **Delayed Emesis:** While Ondansetron is excellent for *acute* emesis (first 24 hours), **Aprepitant** is superior for *delayed* emesis (after 24 hours).

Q: Which of the following is NOT an effect of ranitidine when compared to cimetidine?

Anti-androgenic action. **Explanation:** The question asks to identify which effect is **not** associated with ranitidine when compared to cimetidine. Both drugs are H2-receptor antagonists (H2RAs), but they differ significantly in their side-effect profiles and potency. **1. Why "Anti-androgenic action" is the correct answer:** Cimetidine is notorious for its **anti-androgenic effects**. It binds to androgen receptors and inhibits the metabolism of estradiol, leading to clinical conditions such as **gynecomastia** in men and galactorrhea in women. **Ranitidine**, along with newer H2RAs like famotidine, lacks these anti-androgenic properties. Therefore, ranitidine does not cause these hormonal side effects. **2. Analysis of Incorrect Options:** * **A. Action on H2 receptors:** Both drugs share the same primary mechanism of action—competitive inhibition of histamine at H2 receptors on gastric parietal cells to reduce acid secretion. * **B. Given orally:** Both cimetidine and ranitidine have good oral bioavailability and are commonly administered via the oral route. * **C. Used with proton pump inhibitors:** While not a standard first-line combination (as PPIs are superior), both can theoretically be used in specific refractory cases or "nocturnal acid breakthrough" scenarios, though this is a shared clinical context rather than a differentiating side effect. **High-Yield Clinical Pearls for NEET-PG:** * **Enzyme Inhibition:** Cimetidine is a potent **P450 enzyme inhibitor**, leading to numerous drug interactions (e.g., increasing levels of warfarin, phenytoin, and theophylline). Ranitidine has negligible effects on hepatic enzymes. * **Potency:** Ranitidine is 5–10 times more potent than cimetidine. * **Blood-Brain Barrier:** Cimetidine can cross the BBB, occasionally causing confusion or hallucinations in elderly patients; ranitidine has much lower CNS penetration.

Q: What is true about the proton-pump inhibitor omeprazole?

CYP2C19 predicts efficacy.. **Explanation:**1. Why Option B is Correct:Omeprazole is primarily metabolized in the liver by the cytochrome P450 enzyme **CYP2C19**. Genetic polymorphisms in this enzyme significantly influence the drug's pharmacokinetics. Patients who are "poor metabolizers" (common in Asian populations) have higher plasma concentrations and better acid suppression, whereas "rapid metabolizers" may experience therapeutic failure. Therefore, the CYP2C19 genotype is a major predictor of the drug's clinical efficacy and duration of action [3].2. Why Other Options are Incorrect:* **Option A:** Omeprazole is **highly protein-bound** (approximately 95%), mainly to albumin. This is a common characteristic of most proton pump inhibitors (PPIs).* **Option C:** The oral bioavailability of omeprazole is relatively low, around **35–40%** [1], due to its instability in gastric acid (requiring enteric coating) [2] and significant first-pass metabolism. In contrast, drugs like Lansoprazole or Pantoprazole have higher bioavailability (80% or more).* **Option D:** Since A and C are incorrect, "All of the above" is false.**High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Irreversible inhibition of the **H+/K+ ATPase pump** (the "final common pathway" of acid secretion) [2].* **Activation:** Omeprazole is a **prodrug** that requires an acidic environment (pH < 2) in the canaliculi of parietal cells to be converted into its active form (sulfenamide) [1, 2].* **Administration:** Should be taken **30–60 minutes before a meal** (usually breakfast) to ensure peak plasma levels coincide with the maximal activation of proton pumps.* **Drug Interaction:** Omeprazole inhibits CYP2C19, which can **decrease the activation of Clopidogrel** (a prodrug), potentially increasing the risk of cardiovascular events. Pantoprazole is the preferred PPI when using Clopidogrel.

Question 1

Erythromycin is given in intestinal hypomotility because:

Accepted Answer

It binds to motilin receptors

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenylyl cyclase

Question 2

A patient with diabetic gastroparesis was given erythromycin because of which of the following properties?

Accepted Answer

It imitates motilin

Answer

It increases bacterial count

Answer

It decreases bacterial count

Answer

It binds to adenyl cyclase

Question 3

Ursodiol reduces the size of common bile duct gallstones by which mechanism?

Accepted Answer

Slowly dissolving cholesterol from the stone

Answer

Decreasing the synthesis of bile

Answer

Increasing the cholesterol content in bile

Answer

Chelating Ca2+ out of the stone

Question 4

Which drug is most effective in inhibiting gastric acid output throughout the day?

Accepted Answer

Omeprazole

Answer

Cimetidine

Answer

Pirenzepine

Answer

Misoprostol

Question 5

Aprepitant is used as:

Accepted Answer

Antiemetic

Answer

Antidepressant

Answer

Antihypertensive

Answer

Diuretic

Question 6

All of the following statements are true regarding ondansetron except?

Accepted Answer

It has significant drug interactions.

Answer

It is the antiemetic of choice for chemotherapy-induced vomiting.

Answer

It is a 5-HT3 receptor antagonist.

Answer

It may possess 5-HT4 agonism.

Question 7

All of the following drugs intensify gastrointestinal motility except?

Accepted Answer

Papaverine

Answer

Metoclopramide

Answer

Domperidone

Answer

Cisapride

Question 8

What is the drug of choice for cisplatin-induced emesis?

Accepted Answer

Ondansetron

Answer

Metoclopramide

Answer

Domperidone

Answer

Octreotide

Question 9

Which of the following is NOT an effect of ranitidine when compared to cimetidine?

Accepted Answer

Anti-androgenic action

Answer

Action on H2 receptors

Answer

Given orally

Answer

Used with proton pump inhibitors

Question 10

What is true about the proton-pump inhibitor omeprazole?

Accepted Answer

CYP2C19 predicts efficacy.

Answer

Does not bind to plasma protein.

Answer

Oral bioavailability is 80%.

Answer

All of the above.

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?